| Host: |
Goat |
| Applications: |
Pep-ELISA/IHC |
| Reactivity: |
Human/Rat/Dog/Cow |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Goat polyclonal antibody anti-ILF3 (Internal) is suitable for use in ELISA and Immunohistochemistry research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
0.5 mg/ml in Tris saline, 0.02% sodium azide, pH7.3 with 0.5% bovine serum albumin. NA |
| Purification: |
Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide. |
| Concentration: |
0.5 mg/mL |
| Dilution Range: |
IHC-Recommended concentration, 2-4µg/mlELISA-antibody detection limit dilution 1:32000. |
| Storage Instruction: |
Store at-20°C on receipt and minimise freeze-thaw cycles. |
| Gene Symbol: |
ILF3 |
| Gene ID: |
3609 |
| Uniprot ID: |
ILF3_HUMAN |
| Immunogen Region: |
Internal |
| Accession Number: |
NP_036350.2; NP_060090.2 |
| Specificity: |
This antibody is expected to recognize isoforms a (NP_036350.2) and d (NP_060090.2). |
| Immunogen Sequence: |
QKPSYGSGYQSHQGQ |
| Post Translational Modifications | Phosphorylated at Thr-188 and Thr-315 by PKR in response to certain RNA viruses. This phosphorylation results in the dissociation of ILF2 from the ILF2-ILF3 complex resulting in a cytoplasmic sequestration of ILF3 where it can bind to viral RNAs and impede viral replication. Methylated by protein arginine N-methyltransferase 1. Ubiquitinated at Lys-297 in a TRIM47-dependent manner.this 'Lys-48'-linked ubiquitination promotes ILF3 degradation. |
| Function | RNA-binding protein that plays an essential role in the biogenesis of circular RNAs (circRNAs) which are produced by back-splicing circularization of pre-mRNAs. Within the nucleus, promotes circRNAs processing by stabilizing the regulatory elements residing in the flanking introns of the circularized exons. Plays thereby a role in the back-splicing of a subset of circRNAs. As a consequence, participates in a wide range of transcriptional and post-transcriptional processes. Binds to poly-U elements and AU-rich elements (AREs) in the 3'-UTR of target mRNAs. Upon viral infection, ILF3 accumulates in the cytoplasm and participates in the innate antiviral response. Mechanistically, ILF3 becomes phosphorylated and activated by the double-stranded RNA-activated protein kinase/PKR which releases ILF3 from cellular mature circRNAs. In turn, unbound ILF3 molecules are able to interact with and thus inhibit viral mRNAs. (Microbial infection) Plays a positive role in HIV-1 virus production by binding to and thereby stabilizing HIV-1 RNA, together with ILF3. |
| Protein Name | Interleukin Enhancer-Binding Factor 3Double-Stranded Rna-Binding Protein 76Drbp76M-Phase Phosphoprotein 4Mpp4Nuclear Factor Associated With DsrnaNfarNuclear Factor Of Activated T-Cells 90 KdaNf-At-90Translational Control Protein 80Tcp80 |
| Database Links | Reactome: R-HSA-9762293 |
| Cellular Localisation | NucleusNucleolusCytoplasmLocalizes In The Cytoplasm In Response To Viral InfectionThe Unphosphorylated Form Is Retained In The Nucleus By Ilf2Phosphorylation At Thr-188 And Thr-315 Causes The Dissociation Of Ilf2 From The Ilf2-Ilf3 Complex Resulting In A Cytoplasmic Sequestration Of Ilf3Localized In Cytoplasmic Mrnp Granules Containing Untranslated Mrnas |
| Alternative Antibody Names | Anti-Interleukin Enhancer-Binding Factor 3 antibodyAnti-Double-Stranded Rna-Binding Protein 76 antibodyAnti-Drbp76 antibodyAnti-M-Phase Phosphoprotein 4 antibodyAnti-Mpp4 antibodyAnti-Nuclear Factor Associated With Dsrna antibodyAnti-Nfar antibodyAnti-Nuclear Factor Of Activated T-Cells 90 Kda antibodyAnti-Nf-At-90 antibodyAnti-Translational Control Protein 80 antibodyAnti-Tcp80 antibodyAnti-ILF3 antibodyAnti-DRBF antibodyAnti-MPHOSPH4 antibodyAnti-NF90 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
